TXP Platform Technology
The TXP platform employs low passage human umbilical cord perivascular cells in their native form, harvested and grown entirely in serum-free and xeno-free conditions [WO2004072273]. Unique methods for rapidly dissecting and storing the vessels of the cord with their perivascular tissue are of particular importance for commercial scale-up operations, while maintaining very high viability at harvest. The mesenchymal stem cell frequency in the harvested tissue is 1:300 but increases to 1:3 or 1:4 after passage 2. This allows TRT to generate almost 1 trillion cells by passage 3, and maintain low passage numbers for all eventual applications.
TXP cells are potently anti-inflammatory, and more so than other tissue sources of mesenchymal cells. Inflamed joints – particularly synovial joints – become populated with inflammatory cells. Local delivery of TXP cells radically reduces the number of such cells in the joint (see graph). One mechanism by which TXP cells can be shown to be more anti-inflammatory is that they more efficiently secrete TSG-6 in response to stimulation by TNF-a (see cartoon on graph).
ARDS (Acute Respiratory Distress Syndrome) is a severe inflammatory lung injury for which there is currently no known prevention or cure. More people die of ARDS in intensive care units (ICUs) around the world than for any other reason. Mesenchymal cells from bone marrow and fat have shown considerable promise in the treatment of ARDS. But aging impairs the survival potential of the cells, which restricts their therapeutic efficacy. TRT has a rich source of neonatal mesenchymal cells in the TXP platform, which have demonstrated distinct benefits in ARDS models including increased secretion of TSG-6 and increased survival.